#India #Pune #Tech Mahindra #Pharmacovigilance #NVIDIA

Advancing Drug Safety through AI

In a significant step towards improving drug safety management, Tech Mahindra has partnered with NVIDIA to create a cutting-edge pharmacovigilance solution. This innovative software leverages agentic artificial intelligence and automation, addressing pressing challenges in the pharmaceutical industry such as manual process delays and overwhelming data loads.

The AI-Driven Transformation

Tech Mahindra’s new pharmacovigilance (PV) solution has been meticulously designed using NVIDIA's advanced AI technology, which is integrated into Tech Mahindra's TENO framework. This solution automates essential workflows in pharmacovigilance to ensure the accuracy, speed, and efficiency of case handling, thus transforming the drug safety landscape. By deploying the NVIDIA AI Enterprise software suite, inclusive of resources like NVIDIA NeMo™ and NVIDIA NIM™ microservices, the new framework is set to refine the entire pharmacovigilance process. It smartly manages the intake of cases, data conversion, quality checks, and compliance metrics, all while promoting a streamlined PV workflow.

One of the standout features of this solution is its use of large language model (LLM)-powered AI agents. These agents autonomously oversee case classification, prioritization, and the verification of pharmacovigilance-related communications, thereby minimizing human error and the likelihood of misinformation stemming from manual tasks.

Industry Challenges Addressed

The collaboration between Tech Mahindra and NVIDIA is particularly timely, as the pharmaceutical industry is inundated with vast amounts of data from clinical trials and patient feedback during and after drug launches. With this innovative AI solution, the companies aim to enhance drug safety oversight dramatically. It currently reports processing over 1,000 adverse drug reaction (ADR) cases daily, swiftly flagging and managing issues that may arise post-launch.

For instance, when an email notifying an adverse reaction is sent in, the preserved AI capabilities kick in and treat the request with urgency, eliminating human delays that typically hinder quick responses. The result is an impressive reduction in processing times of up to 40%, improved data accuracy by 30%, and operational cost reductions of approximately 25%. Such advancements ensure not only regulatory compliance but enable proactive identification of potential risks, shifting the paradigm from reactive to predictive pharmacovigilance.

Expert Insights from Industry Leaders

Experts from both companies are enthusiastic about this game-changing solution. Nikhil Malhotra, Chief Innovation Officer and Global Head of AI and Emerging Technologies at Tech Mahindra, commented, “Our partnership with NVIDIA is pioneering new paths in pharmacovigilance. The combination of generative AI and multi-agent systems allows us to enhance drug safety management processes efficiently, assuring better outcomes for our clients.”

On NVIDIA's side, John Fanelli, Vice President of Enterprise Software, emphasized, “AI proves essential in monitoring drug safety throughout their lifecycle. The integration of NVIDIA AI technology within Tech Mahindra's solutions significantly strengthens pharmacovigilance by facilitating human capabilities in recognizing safety problems.”

Looking Forward

Tech Mahindra continues to enhance its TENO framework, broadening its capabilities through ongoing collaboration with NVIDIA. This partnership adds tailored AI agents designed to tackle a wide array of industry-specific challenges. With the integration of tools like NVIDIA NeMo™, which accelerates AI development pipelines, and Tech Mahindra's own VerifAI for comprehensive data governance, the framework is set to adapt continuously, ensuring that the AI systems remain at the forefront of decision-making processes.

The collaboration between Tech Mahindra and NVIDIA marks an exciting chapter in the world of drug safety management. By harnessing the power of artificial intelligence, they are not only simplifying complex processes but also reshaping how the pharmaceutical industry approaches drug safety.